Screening for MAFLD: who, when and how?
| Autor: | Shreya C. Pal, Nahum Méndez-Sánchez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Endocrinology and Metabolism, Vol 14 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2042-0196 20420188 |
| DOI: | 10.1177/20420188221145650 |
| Popis: | Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this disease poses a major health burden. MAFLD as a spectrum of diseases can range from simple steatosis, and steatohepatitis to fibrosis and hepatocellular carcinoma. Its extra-hepatic manifestations are vast and include cardiovascular diseases, extra-hepatic malignancies, cognitive and respiratory alterations. Given its extensive damage targets as well as its high prevalence, timely identification of the high-risk population presenting metabolic dysfunction should undergo universal non-invasive screening methods, which can be carried out through blood tests, easy and effective imaging techniques, such as ultrasound, score calculation and general clinical information brought together from primary patient–physician contact. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|